Immutep Announces Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting
Immutep Announces Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting
Immutep Announces Data From Phase II Trial In Soft Tissue Sarcoma Presented At CTOS 2024 Annual Meeting; Efti In Combination With Pembrolizumab And Radiotherapy Demonstrates Significant Efficacy In The Neoadjuvant Setting In Patients With Soft Tissue Sarcoma
Immutep宣布在2024年CTOS年会上发布的软组织肉瘤二期试验数据；在新辅助治疗中，Efti联合佩姆布罗利珠单抗和放疗显示出显著的疗效。
- Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcoma
- Over three-fold increase in tumour hyalinization, the primary endpoint of the study and an important predictor of overall survival, as compared to historical results from radiotherapy alone
- Efti联合佩姆布罗利珠单抗和放疗在软组织肉瘤患者的新辅助治疗中显示出显著的疗效。
- 与仅用放疗的历史结果相比，肿瘤透明化的增幅超过三倍，这是研究的主要终点，也是总体生存的重要预测指标。
SYDNEY, AUSTRALIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus KEYTRUDA (pembrolizumab) for patients with soft tissue sarcoma (STS), at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant setting for resectable STS.
悉尼， 澳洲，2024年11月14日（环球新闻通讯社）—— Immutep有限公司（（ASX：IMm，纳斯达克：IMMP）（"Immutep"或"公司"），一家临床阶段的生物技术公司，致力于开发新型LAG-3免疫疗法用于癌症和自身免疫疾病，今日宣布在2024年结缔组织肿瘤学会（CTOS）年会上展示EFTISARC-NEO研究的新数据，该研究为二期研究，由研究者发起，评估eftilagimod alpha（efti）联合放疗和KEYTRUDA（佩姆布罗利珠单抗）用于软组织肉瘤（STS）患者。基于对21名可供主要终点评估的患者的初步分析，三重联合疗法在可切除的STS新辅助治疗中显示出显著疗效。
